352 results on '"Monif, Mastura"'
Search Results
2. Language impairments in seropositive and seronegative autoimmune encephalitis
3. Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study
4. P2X7 receptor antagonism by AZ10606120 significantly depletes glioblastoma cancer stem cells in vitro
5. CLADIN- CLADribine and INnate immune response in multiple sclerosis – A phase IV prospective study
6. Cognitive and psychopathological features of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease: A narrative review
7. P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma
8. MicroRNAs in adult high-grade gliomas: Mechanisms of chemotherapeutic resistance and their clinical relevance
9. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review
10. Neutropaenia complications from Ocrelizumab and Rituximab treatment
11. Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitis
12. A comprehensive review of the advances in neuromyelitis optica spectrum disorder
13. Cognition following chimeric antigen receptor T-cell therapy: A systematic review
14. Serum neurofilament light as a biomarker of vulnerability to a second mild traumatic brain injury
15. Cognitive and psychopathological outcomes in acute disseminated encephalomyelitis
16. Psychiatric manifestations of autoimmune encephalitis
17. Rare antibody-mediated and seronegative autoimmune encephalitis: An update
18. Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitis
19. Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides
20. Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
21. Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis
22. Electroclinical biomarkers of autoimmune encephalitis
23. Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
24. Relapse Determinants in Seropositive and Seronegative Neuromyelitis Optica Spectrum Disorder (P10-14.016)
25. Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic
26. Clinical outcomes among initial survivors of cryptogenic new‐onset refractory status epilepsy (NORSE)
27. Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies
28. Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
29. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer
30. Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE)
31. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.
32. The need to incorporate aged animals into the preclinical modeling of neurological conditions
33. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review
34. Repetitive mild traumatic brain injury elicits a reactive microglial morphology and elevates serum neurofilament light levels, independent of NLRP3 inflammasome inhibition
35. Inflammatory complications of CGRP monoclonal antibodies: a case series
36. P2X7 receptor antagonism inhibits tumour growth in human high-grade gliomas
37. Development and Validation of a Peripheral Cell Ratio and Lactate Score for Differentiating Status Epilepticus from Prolonged Psychogenic Non‐Epileptic Seizures
38. Cognitive and psychopathological outcomes in acute disseminated encephalomyelitis
39. 2623 Prevalence of movement disorders in autoimmune encephalitis: a systematic review and meta-analysis
40. 2710 Effects of purinergic P2X receptor 7 (P2X7R) inhibition in glioblastoma
41. 2808 Exploring the uptake, and real-world efficacy of intramuscular tixagevimab150mg/150mg cilgavimab (EvusheldTM) in multiple sclerosis patients (pwMS) during COVID 19 pandemic
42. 8 Cervical abnormality risk increases in women with MS treated with high-efficacy disease modifying therapy
43. 7 CLADIN: CLADribine and INnate immune responses in multiple sclerosis
44. 20 Changes in mRNA expression in the temporal lobe of patients with drug resistant epilepsy: a focus on neuroinflammation
45. 2785 Executive dysfunction in patients with autoimmune encephalitis – a study of Australian autoimmune encephalitis consortium
46. 6 Spike antibody seroconversion and emerging variant cross-reactivity following COVID-19 third vaccination dose in Australian people with multiple Sclerosis
47. 2781 Memory outcomes in patients with autoimmune encephalitis – a study of the Australian autoimmune encephalitis consortium
48. Inhibition of purinergic P2X receptor 7 (P2X7R) decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) expression in U251 glioblastoma cells
49. Clinical factors associated with the yield of routine outpatient scalp electroencephalograms: A retrospective analysis from a tertiary hospital
50. Movement disorders in cell surface antibody mediated autoimmune encephalitis: a meta-analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.